Quantcast

Research Opens Door To New Thrombosis Treatments

December 10, 2009

The latest findings on how blood clots form could open the door to the development of new and better-targeted drugs for patients at risk of strokes or heart attacks.

Many of these patients currently take anticoagulant drugs such as Warfarin, which lower the risk of heart attacks or strokes by reducing the blood’s ability to clot.

Although these drugs reduce the risk of dangerous blood clot formation within blood vessels (thrombosis), they also affect normal wound healing, leaving patients at risk of lethal bleeding if they injure themselves in any way.

Now, a team of scientists from the UK, Sweden, Germany, Holland and the USA have discovered that the molecule polyphosphate can affect blood clot formation within veins and arteries without changing our ability to heal.

The findings, published this week in the journal Cell, are the first to show that polyphosphate activates a blood clotting agent called factor XII which is involved in the formation of harmful clots within blood vessels. But factor XII is not involved in surface wound healing and therefore reducing its levels in the body would not increase the risk of excessive bleeding.

The discovery opens up opportunities for drug development, according to Dr Nicola Mutch from the University of Leeds who carried out the UK branch of the research.

“The challenge in designing treatments to reduce thrombosis is getting the balance right. We need to find an appropriate drug level or target which causes enough anticoagulation to prevent risk of heart attack or stroke but with minimal bleeding side effects,” she explains.

“Our work suggests polyphosphate or factor XII could be potential new targets, as neither seems to affect our ability to heal naturally, so drugs based on these molecules could offer a major improvement on existing treatments.”

On the Net:




comments powered by Disqus